Scotiabank raised the firm’s price target on Argenx to $402 from $346 and keeps a Sector Perform rating on the shares. The firm says the Q4 and fiscal 2023 Vyvgart revenues in line with the earlier preannouncement as it await sresults from three Phase 2 trials evaluating efgart in Sjogren’s, myositis and post-Covid POTS later this year.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ARGX:
- Argenx reports Q4 EPS ($1.68), consensus ($1.70)
- argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
- ARGX Upcoming Earnings Report: What to Expect?
- argenx to Present at Upcoming Investor Conferences
- argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
